Regeneron Pharms Stock
StockStockPrice
Frequently asked questions
What is Regeneron Pharms's market capitalization?
What is Regeneron Pharms's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Regeneron Pharms?
What are the analyst ratings and target price for Regeneron Pharms's stock?
What is Regeneron Pharms's revenue over the trailing twelve months?
What is the EBITDA for Regeneron Pharms?
What is the free cash flow of Regeneron Pharms?
What is the 5-year beta of Regeneron Pharms's stock?
How many employees does Regeneron Pharms have, and what sector and industry does it belong to?
What is the free float of Regeneron Pharms's shares?
Financials
Market Cap
$90.73B5Y beta
0.11EPS (TTM)
$40.42Free Float
106.38MP/E ratio (TTM)
20.43Revenue (TTM)
$13.85BEBITDA (TTM)
$4.66BFree Cashflow (TTM)
$3.32BPricing
Analyst Ratings
The price target is $1,065.66 and the stock is covered by 27 analysts.
Buy
19
Hold
7
Sell
1
Information
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
13,450
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker